drugset / Trial / NCT06594991
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
Phase 2
Recruiting
88 enrolled
Memorial Sloan Kettering Cancer Center
Regeneron Pharmaceuticals · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.
Timeline
- Start
- 2024-09-10
- Primary completion
- 2027-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | — | Intravenous |
| Subject | Fianlimab | Monoclonal antibody | — | Intravenous |
| Subject | Ipilimumab | Monoclonal antibody | — | — |